期刊
GUT
卷 59, 期 4, 页码 496-507出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/gut.2008.169805
关键词
-
资金
- Israeli Academy of Sciences
- Association for International Cancer Research (AICR)
- Ministry of Justice, Israel [0113406]
- Israel Cancer Research Fund (ICRF)
- Israel Cancer Research fund
- NIH [R03CA113252]
- Recanati Foundation
- NATIONAL CANCER INSTITUTE [R03CA113252] Funding Source: NIH RePORTER
Adenomatous polyposis coli (APC) is a multifunctional tumour suppressor protein that negatively regulates the Wnt signalling pathway. The APC gene is ubiquitously expressed in tissues and organs, including the large intestine and central nervous system. The majority of patients with sporadic and hereditary colorectal cancer have mutations in the gene encoding APC. Approximately 30% of these mutations are single nucleotide changes that result in premature stop codons (nonsense mutations). A potential therapeutic approach for treatment of this subset of patients is the use of aminoglycosides and macrolides that induce nonsense mutation read-through and restore levels of full-length protein. We have used reporter plasmids and colorectal cancer cell lines to demonstrate that several aminoglycosides and tylosin, a member of the macrolide family, induced read-through of nonsense mutations in the APC gene. In xenograft experiments and in the Apc(Min/+) mouse model, these compounds ameliorated the tumorigenic clinical symptoms caused by nonsense mutations in the APC gene.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据